Oncoheroes Biosciences
Oncoheroes Biosciences is dedicated to developing new therapies for childhood cancer, with a focus on advancing drugs like Dovitinib and Volasertib through clinical trials and partnerships.
Services
Oncoheroes Biosciences focuses on delivering new therapies for childhood cancer. Their services span drug discovery, using precision oncogenic targets to identify potential drug combinations, to clinical development, which involves in-licensing clinic-ready assets for rapid regulatory approval. The company's proprietary pediatric screening platform, developed in their Barcelona Science Park discovery lab, is validated for medulloblastoma group 3 and is being scaled for other pediatric cancers.
Products
Oncoheroes Biosciences has a robust pipeline of products aimed at treating various pediatric cancers. Key compounds include Volasertib for Alveolar Rhabdomyosarcoma and Dovitinib for Osteosarcoma, both of which are in clinical trials. Additional projects within their pipeline target a diverse range of pediatric solid tumors, neuroblastoma, sarcomas, and CNS tumors, including the use of Stenoparib. Key product developments are supported by partnerships and significant funding from various foundations.
Partnerships
Oncoheroes Biosciences partners with numerous organizations to advance their therapeutic initiatives. Collaborations include the Hopp Children's Cancer Center Heidelberg (KiTZ), pharmaceutical industries, and various foundations and patient associations. These partnerships support the development of novel therapies and clinical trials. Additionally, Oncoheroes is a member of the Coalition Against Childhood Cancer (CAC2) and an associate member of the i4KIDS Pediatric Innovation Hub in Barcelona.
Founding and Financial Support
Oncoheroes Biosciences has garnered financial support from a range of foundations since its inception. The National Foundation for Cancer Research funded their drug discovery lab in 2017. Subsequent investments have come from the Andrew McDonough B+ Foundation, Gregory Foundation for Cancer Research, Super Sam Foundation, and numerous others. These investments have been pivotal in advancing their pipeline and scaling their pediatric oncology research initiatives.
Clinical Trials and FDA Designations
Oncoheroes Biosciences is advancing several clinical trials focused on pediatric oncology. Dovitinib, aimed at treating osteosarcoma, has received Orphan Drug Designation from the U.S. FDA. The company has been approved to initiate two pediatric oncology clinical trials by the FDA. Their lead compound, Volasertib, is being tested in collaboration with Hopp Children's Cancer Center Heidelberg (KiTZ) for its efficacy against multiple pediatric cancers, such as Rhabdomyosarcoma.